INDGN Share Price Performance
₹0
-577.05 (-100.00%)
Price ₹0
Fair Value₹808.94
Share Pricen/a
Narrative Update • Jun 17
Indegene Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
INDGN Community Narratives
MA
Fair Value
·Fair Value ₹808.94 36.8% undervalued intrinsic discount
Indegene deep undervalued stock
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value ₹592.43 13.7% undervalued intrinsic discount
Digital Transformation And AI Adoption Will Expand Pharma Market
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value
·Fair Value ₹490 4.3% overvalued intrinsic discount
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Indegene deep undervalued stock
At ₹429–430 levels (near 52-week low), Indegene offers excellent risk-reward for 12–24 month horizon. Explosive long-term growth (35% sales CAGR, 68% profit CAGR), first $100M quarter, near-zero debt, and powerful AI/GenAI positioning in the high-growth life-sciences sector make this a high-quality compounder.Read more
MA
₹808.94
36.8% undervalued intrinsic discount
Fair Value
Revenue
15.98% p.a.
Profit Margin
13.46%
Future PE
40x
Price in 2031
₹1.54k
Digital Transformation And AI Adoption Will Expand Pharma Market
Drug companies are leaning into digital tools and AI to cut costs and move faster, and Indegene is positioning itself as a go-to partner for that shift. The upside depends on whether big pharma clients adopt these new services quickly and don’t pull back spending, since a few large customers and project delays can still swing results.Read more
AN
₹592.43
13.7% undervalued intrinsic discount
Fair Value
Revenue
16.36% p.a.
Profit Margin
13.53%
Future PE
28.06x
Price in 2029
₹868.83
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?Read more
AN
₹490
4.3% overvalued intrinsic discount
Fair Value
Revenue
16.09% p.a.
Profit Margin
13.82%
Future PE
24.51x
Price in 2029
₹722.17
Trending Discussion
No trending discussion available.
Recently Updated Narratives
MA
Indegene deep undervalued stock
Fair Value: ₹808.94 36.8% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
INDGN: Tax Resolution Progress And Final Dividend Plans Will Support Upside
Fair Value: ₹592.43 13.7% undervalued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Fair Value: ₹490 4.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Indegene Limited Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 30, 2026
- 16.71
- 100.00%
- 11.43%
- 0%
About INDGN
- Founded
- 1998
- Employees
- 4158
- CEO
- WebsiteView website
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
Recent INDGN News & Updates
Narrative Update • Jun 02
